Literature DB >> 35221475

Practicable Measurement and Identification of Overbasalization.

Kevin Cowart1,2,3, Nicholas W Carris1,4.   

Abstract

Entities:  

Year:  2022        PMID: 35221475      PMCID: PMC8865788          DOI: 10.2337/cd21-0096

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN: 0891-8929


× No keyword cloud information.
  17 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 2.  Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Authors:  Kevin Cowart
Journal:  Clin Diabetes       Date:  2020-07

3.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Jeffrey S Riesmeyer; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

4.  When basal insulin is not enough: response to M Davidson.

Authors:  Guillermo E Umpierrez; Neil Skolnik; Terry Dex; Louise Traylor; Jason Chao; Charles Shaefer
Journal:  Diabetes Obes Metab       Date:  2019-12-05       Impact factor: 6.577

Review 5.  Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.

Authors:  Nicholas W Carris; James R Taylor; John G Gums
Journal:  Drugs       Date:  2014-12       Impact factor: 9.546

6.  Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.

Authors:  Jessica A Huthmacher; Juris J Meier; Michael A Nauck
Journal:  Diabetes Care       Date:  2020-09       Impact factor: 19.112

7.  Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.

Authors:  Kevin Cowart; Wendy H Updike; Rashmi Pathak
Journal:  Clin Diabetes       Date:  2021-04

Review 8.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Authors:  R Balena; I E Hensley; S Miller; A H Barnett
Journal:  Diabetes Obes Metab       Date:  2012-11-12       Impact factor: 6.577

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  How much is too much? Outcomes in patients using high-dose insulin glargine.

Authors:  T Reid; L Gao; J Gill; A Stuhr; L Traylor; A Vlajnic; A Rhinehart
Journal:  Int J Clin Pract       Date:  2015-11-13       Impact factor: 2.503

View more
  1 in total

1.  Clinical Overbasalization Revisited.

Authors:  Mayer B Davidson
Journal:  Clin Diabetes       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.